WuXi XDC Cayman (HKG:2268) expects a net profit of 260% higher in 2024 than in 2023, a Wednesday Hong Kong bourse filing said.
The company also expects its revenue for the reporting year to jump 85% compared with the year prior.
The antibody-drug conjugates company attributed the surge in its expected net profit and revenue for the reporting period to steady downstream demand from the fast growth of antibody-drug conjugate and the expanded bio-conjugate industry.
The group also attributed the higher gains for 2024 to its competitive strength and increased profit margins for the reporting period resulting from improved production efficiency.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。